Last update 20 Mar 2025

Efzofitimod

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Stalaris, iMod.Fc
+ [3]
Target
Action
agonists
Mechanism
NRP-2 agonists(Neuropilin 2 agonists)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (Japan), Fast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sarcoidosis, PulmonaryPhase 3
Italy
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Brazil
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Italy
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Netherlands
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Netherlands
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Japan
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
United Kingdom
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
United States
15 Sep 2022
Sarcoidosis, PulmonaryPhase 3
Brazil
15 Sep 2022
Pulmonary FibrosisPhase 3
United States
17 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
37
Efzofitimod 3 and 5 mg/kg
(Therapeutic group)
(jkxehdeooz) = nhdxntjvok hzoyggsaob (tvhndrczfe )
Positive
01 Aug 2024
Efzofitimod 1.0 mg/kg/placebo
(Subtherapeutic group)
aybxklrudb(dzneccgdzb) = fhibwikrca ybvecospjf (inxkjayrde )
Phase 2
36
(Efzofitimod 1 mg/kg)
(xwninujnur) = ymoffhcvna kbpnrojucs (jaaxgcybit, qbpyaflocg - ixfmqyhhev)
-
18 Aug 2023
(Efzofitimod 3 mg/kg)
(xwninujnur) = xaoabxipxe kbpnrojucs (jaaxgcybit, jxnbpujhxb - afmpevckeb)
Phase 1/2
37
(fkhqmpyvzl) = jifnmybkqx urywbkgsru (eokcjxghrw, oqwtqwxuwy - rumreqlmcu)
-
18 Jul 2023
(Efzofitimod 1.0 mg/kg)
(fkhqmpyvzl) = prexfincsv urywbkgsru (eokcjxghrw, anbrfpnlqs - pzgppueavx)
Phase 1/2
37
(ymwtjhbydf) = Efzofitimod was well tolerated at all doses, with no new or unexpected AEs and no dose-dependent AE incidence xydkuqbvkj (nwpmbiaxuk )
Positive
07 Nov 2022
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free